VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas
Status:
Terminated
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This study is to determine the safety and effectiveness of VTX-2337 (an investigational drug
that stimulates the immune system) in combination with radiation therapy in treating patients
with low-grade B-cell lymphoma. Patients will receive 2 low doses of radiotherapy, and 9
intratumoral injections of VTX-2337 over the course of 3 months.